Abre Venous Stent Meets 30-Day, 1-Year Targets in Pivotal IDE Trial | SCAI

Jun 18th 2020 | News & Clinical Trials

Abre Venous Stent Meets 30-Day, 1-Year Targets in Pivotal IDE Trial

Venous Disease

If approved by the FDA, this device will join two others designed specifically for use in the veins.

From tctMD.com

Read article—tctMD

Other Specialist Resources for Peripheral Vascular Disease

Including recently published studies, coverage of late-breaking science, updates from clinical trials and registries, and complex case presentations.

Clinical Interest Article

Clinical Outcomes of Blood Return During Continuous Aspiration Mechanical Thrombectomy for Pulmonary Embolism: Full Comparative Safety and Efficacy Analysis from ENGULF—Coverage of SCAI Scientific Sessions 2026

Clinical Interest Article

6-Month Outcomes of the CARPOOL Study: Radial-to-Peripheral Versus Femoral Access in Lower Extremity PAD Revascularization—Coverage of SCAI Scientific Sessions 2026

Clinical Interest Article

The SirPAD Trial: Sirolimus-Coated Balloon Angioplasty for Infrainguinal Artery Disease—Coverage of ACC 2026

Clinical Interest Article

The HI-PEITHO Trial: Ultrasound-Facilitated Catheter-Directed Thrombolysis vs. Anticoagulation Alone for Acute Intermediate- High-Risk Pulmonary Embolism—Coverage of ACC 2026

Clinical Interest Article

The CARPOOL Study: Comparison of Radial to Peripheral and Femoral Artery Approaches for Revascularization of Lower Limb Arteries—Coverage of CRT 2026

Clinical Interest Article

Evaluating Standard Shielding vs. Novel Enhanced Radiation Protection Devices in the Cath Lab—Coverage of CRT 2026

© Society for Cardiovascular Angiography & Interventions

SCAI^® is a registered trademark of the Society for Cardiovascular Angiography & Interventions.

All content found on the Society for Cardiovascular Angiography & Interventions website (www.scai.org) including text, images, audio, video, or other formats is created for informational purposes only. Links to other content are to be taken at your own risk. SCAI is not responsible for the content or claims of external websites.

Get in touch

2001 L Street NW, Suite 500 PMB50672, Washington, DC 20036

202-741-9854 TEL

800-992-7224 TOLL-FREE

800-863-5202 FAX

[email protected]

Connect

Follow us on social media.